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PPARg: An Essential Regulator Minireview
of Adipogenesis and Modulator
of Fat Cell Function
PPARg, a member of the PPAR subfamily of nuclear
hormone receptors, heterodimerizes with the retinoid X
receptor a (RXRa) to promote gene expression. Like
C/EBPa, PPARg is not expressed in preadipocytes (or
is expressed at low levels) and is turned on during differ-
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entiation, prior to the expression of most adipocyte
genes, many of which contain PPAR-binding sites (re-
viewed in Spiegelman, 1998; Auwerx, 1999). It is interest-Introduction
ing to note that many of these genes also contain C/EBP-The most important function of adipose tissue is its
binding sites, providing a ªdouble-doseº of transcriptionability to store and release fat during periods of feeding
factor±binding sites.and fasting. This allows food intake to be intermittent,
Like most members of the nuclear receptor family,freeing up time for other activities, and provides a life-
PPARg activity is regulated by ligands. Endogenous li-saving buffer against protracted periods of famine. That
gands identified to date have relatively low affinity (2±50humans are capable of surviving months of total starva-
mM) and are fatty acid±like compounds such as prosta-tion reflects the awesome storage capacity and survival
noid derivatives of arachadonic acid (15-deoxyD12,14PGJ2),advantage of adipose tissue. However, modern times
polyunsaturated fatty acids (linoleic acid), and oxidizedwith the abundance of food and decreased opportunity
forms of linoleic acid (9- and 13-hydroxyoctadecadie-for physical activity have exposed a significant disad-
noic acid) (Forman et al., 1995; Kliewer et al., 1995; Nagyvantage to energy storage in adipose tissue, namely
et al., 1998). Whether other endogenous ligands withobesity, with its associated morbidities of heart disease,
higher affinity exist remains to be established. Pharma-non-insulin-dependent diabetes mellitus (NIDDM) and
ceutical ligands include the thiazolidinediones (TZDs)high blood pressure. With this in mind, there has been
such as troglitazone, BRL49653 (rosiglitazone), and pi-intense interest in elucidating the mechanisms control-
oglitazone. This clinically useful class of compoundsling adipose tissue development. Three recent papers
was developed independently as insulin sensitizers forin the October issue of Molecular Cell highlight the criti-
the treatment of insulin resistance in patients withcal role played by PPARg (peroxisome proliferator-acti-
NIDDM. Only subsequently was it discovered that thevated receptor-g) in this process (Barak et al., 1999;
molecular target of TZDs is PPARg (Forman et al., 1995;Kubota et al., 1999; Rosen et al., 1999).
Insight from Adipogenic Cell Lines reviewed in Kliewer et al., 1995). The mechanism by
which TZD-mediated stimulation of PPARg improvesApproximately 25 years ago, mouse fibroblast cell lines
were established that could differentiate into adipocytes insulin resistance is an important, active area of investi-
gation.under certain tissue culture conditions, such as the addi-
tion of glucocorticoids, agents that increase cAMP, C/EBPs, PPARg, and Adipogenesis:
Gain-of-Function Experimentsagonists of the IGF-1 receptor, and fetal bovine serum.
Using these cell lines, 3T3-L1 and 3T3-F442A preadipo- Unlike 3T3-L1 and 3T3-F442A adipocytes, NIH-3T3 fi-
broblasts are relatively resistant to adipogenesis andcytes, it was found that differentiated adipocytes ex-
press many mRNA transcripts that are not found in pre- do not express C/EBPa or PPARg, and only low levels
of C/EBPb and C/EBPd. Forced ectopic expression ofadipocytes. ªAdipocyte-specificº genes were cloned
and their promoter/enhancer regions explored. One of either C/EBPa, C/EBPb, or PPARg alone stimulates adi-
pogenesis, while C/EBPd works synergistically withthese genes, the adipocyte-specific fatty acid±binding
protein gene (aP2), has been well characterized, and C/EBPb (Freytag, 1994; Tontonoz, 1995; Yeh, 1995; Wu,
1996). Also, marked synergy is observed when C/EBPaits promoter has binding sites for each of the two
major adipogenic transcription factors, C/EBPa (CCAAT/ and PPARg are coexpressed. These studies provided
important insight into the existence of cascades (C/EBPbenhancer binding protein-a) and PPARg.
C/EBPa belongs to a large family of transcription fac- and C/EBPd inducing PPARg expression), positive cross-
regulation loops (PPARg inducing C/EBPa expression andtors possessing basic leucine zipper (bZIP) domains.
C/EBPa is not expressed in preadipocytes but is turned vice versa), and possibly autoregulatory loops (C/EBPa
and PPARg inducing their own expression) that all pro-on during differentiation, prior to the expression of most
adipocyte genes, many of which contain C/EBP-binding mote and maintain the differentiated state.
C/EBPs, PPARg, and Adipogenesis:sites (reviewed in Mandrup and Lane, 1997). Two other
members of the C/EBP family are also expressed during Loss-of-Function Experiments
C/EBPb and C/EBPd. C/EBPb and C/EBPd are inducedadipogenesis, C/EBPb and C/EBPd, but at a time pre-
ceding the expression of C/EBPa (Yeh et al., 1995; during early stages of differentiation and this is thought
to induce expression of PPARg and C/EBPa, culminat-Mandrup and Lane, 1997). It was proposed that early
induction of C/EBPb and C/EBPd relays hormonal stimu- ing in the terminal differentiation of adipocytes. As a
test of this, Tanaka et al. (1997) generated gene knock-lation of adipocyte differentiation to downstream ef-
fectors, possibly C/EBPa and PPARg, whose gene pro- out mice lacking either C/EBPb, C/EBPd, or both
C/EBPb and C/EBPd. Neonatal lethality occurred in 35%moters bear binding sites for members of the C/EBP
family (Yeh et al., 1995; reviewed in Mandrup and Lane, of C/EBPb 2/2 mice and 85% of C/EBPb/d double
knockout mice. Animals surviving past the first 24 hr1997).
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were viable well into adulthood. White adipose tissue E15.5 PPARg 2/2 embryo, and one live born PPARg
2/2 mouse. The cardiac phenotype was rescued in thedepots were nearly normal in the single knockout mice,
but were reduced in weight by 70% in the C/EBPb/d embryos demonstrating that it was secondary to placen-
tal dysfunction. Of note, the E15.5 2/2 embryo, similardouble knockout mice. Remarkably, mRNA levels of
C/EBPa, PPARg, and adipocyte-specific genes such as to the 1/2 embryo, showed expression of a b-galactosi-
dase reporter cassette, which had been inserted in-aP2 were normal in the small depots of double knockout
mice. This finding suggests that other pathways must frame into the PPARg coding region of the gene-tar-
geting construct. b-galactosidase activity was noted inbe capable of triggering PPARg and C/EBPa expression,
and hence adipocyte differentiation. ADD-1/SREBP-1, an anatomical location where brown fat subsequently
appears in normal but not the 2/2 live-born mouse,a key transcription factor in sterol regulation, is one
candidate mediator of a C/EBPb and C/EBPd-indepen- raising the interesting possibility that brown adipocyte
precursors begin to develop, but fail to elaborate intodent pathway since it binds to the PPARg promoter and
induces its expression (Fajas et al., 1999). Also, gene brown adipose tissue in the absence of PPARg. Histo-
logical analysis will be required to better understandexpression induced by ADD-1/SREBP-1 leads to the
production of PPARg ligands (Kim et al., 1998). the nature of these E15.5 b-galactosidase-positive cells.
The live-born PPARg 2/2 mouse was a runt weighingC/EBPa. The first loss-of-function experiment was ex-
pression of antisense C/EBPa mRNA in 3T3-L1 adipo- 70% of a similarly created PPARg 1/2 littermate. The
health of the runt deteriorated at day P5, and at daycytes. This maneuver reduced expression of endoge-
nous C/EBPa mRNA and protein, resulting in markedly P6.5 was examined along with the 1/2 littermate. The
PPARg-deficient mouse was notable for total absencereduced expression of aP2 mRNA and protein, and de-
creased triglyceride accumulation (reviewed in Mandrup of white and brown adipose tissue (complete lipodystro-
phy) and fatty liver (secondary to lipodystrophy). Al-and Lane, 1997). This observation was confirmed and
extended in gene knockout mice lacking C/EBPa that though the number is small, the conclusion is profound:
PPARg is required for adipogenesis in vivo.fail to develop normal depots of adipose tissue (Wang
et al., 1995). Adipocytes are present in C/EBPa-deficient A similarly profound conclusion was provided in the
study by Rosen et al. (1999) in which chimeric mice ofmice, but are relatively devoid of triglyceride, indicating
that C/EBPa is not required for adipogenesis, per se, a more conventional kind were generated by injecting
ES cells homozygous for PPARg deficiency into PPARgbut plays an important role in the terminal maturation
of fat cells. Additional support for this view comes from 1/1 blastocysts. The authors observed that PPARg 2/2
ES cells contributed significantly to the composition offibroblast cells isolated from C/EBPa 1/1 and 2/2 em-
bryos. Virally mediated ectopic expression of PPARg a number of tissues, including heart, spleen, small intes-
tine, and skeletal muscle, but contributed poorly to adi-plus treatment with the agonist troglitazone stimulated
adipogenesis in greater than 70% of 1/1 and 2/2 cells. pose depots (which consist of adipocytes plus other
cells) and hardly at all to mature adipocytes within theHowever, 2/2 cells accumulated less triglyceride, showed
impaired insulin-stimulated glucose uptake, and did not depot. In addition, the authors observed that PPARg
null ES cells are unable to contribute to the sebaceousinduce endogenous PPARg mRNA, confirming that
C/EBPa is not required for adipogenesis, but that glands of the skin, suggesting an important role of
PPARg in their development as well.C/EBPa and induction of PPARg by C/EBPa are required
to develop the fully differentiated state (Wu, 1999). In vitro fat cell differentiation assays also confirmed
the important role of PPARg. Using fibroblasts isolatedPPARg. The field has eagerly awaited the results of
gene knockout efforts aimed at proving the role of from PPARg 1/1, 1/2, and 2/2 embryos (Kubota et
al., 1999) or ES cells of similar genotypes (Rosen etPPARg in adipogenesis and uncovering its possible
physiologic role in regulating insulin sensitivity. Such al., 1999), it was observed that PPARg null cells (fibro-
blasts or ES cells) expressed normal levels of C/EBPbassessments, however, have been delayed due to an
unexpected requirement of PPARg for placental devel- and C/EBPd in response to the differentiation proto-
col, but compared to wild-type cells had reduced oropment (Barak et al., 1999; Kubota et al., 1999). Indeed,
PPARg, specifically the g1 isoform, is expressed in the very low levels of C/EBPa and completely failed to in-
duce expression of aP2 and leptin, or to accumulatediploid trophoblast lineages, and its deficiency leads to
placental dysfunction and death by E10. Prior to death, lipid. Heterozygous fibroblasts and ES cells showed
an intermediate impairment of adipogenesis. These inplacental deficiency causes severe myocardial thinning,
presumably due to impaired supply of fuel and/or oxy- vitro loss-of-function experiments strongly support the
view that PPARg is downstream of C/EBPb and C/EBPd,gen. Interestingly, qualitatively similar placental and car-
diac abnormalities are seen in RXRa knockout and but upstream of C/EBPa and terminal fat cell differentia-
tion. A schematic model reflecting this view is shown inRXRa/RXRb double knockout mice, suggesting that
these phenotypes may be due to impaired PPARg-medi- Figure 1.
Roles of PPARg and C/EBPa in Fully Differentiated,ated signaling in the placenta.
To circumvent placental lethality, Barak et al. (1999) Mature Adipocytes
Since the adipocyte ªphenotypeº is a byproduct of theisolated PPARg 2/2 6- to 8-cell embryos and aggre-
gated these with tetraploid PPARg 1/1 preimplantation genes it expresses, and since the expression of these
ªadipocyte-specificº genes is controlled primarily byembryos. In such chimeras, tetraploid cells (in this case
PPARg 1/1 cells) are unable to contribute to the embryo PPARg and C/EBPa, it stands to reason that these tran-
scription factors regulate function of mature adipocytesproper, but their contribution to extraembryonic tissues
tends to be extensive. By such efforts, Barak et al. were as well as adipogenesis. However, this aspect of PPARg
and C/EBPa has been relatively unexplored. A case inable to generate two E12.5 PPARg 2/2 embryos, one
Minireview
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as occurs in models of lipodystrophy. Along these lines,
it is important to note that high fat diet±induced fatty
liver was present in wild-type mice, but was prevented
in PPARg 1/2 mice, a condition that would worsen if
adipocyte lipid storage was limiting. As an alternative
mechanism, Kubota et al. (1999) report that leptin mRNA
and circulating protein levels are elevated in high fat±fed
PPARg 1/2 mice, possibly due to decreased PPARg-
mediated inhibition of leptin gene expression. In support
of this, the authors show that differentiated embryo
fibroblasts heterozygous for PPARg, compared to wild-
type cells, have increased leptin mRNA levels and in-
creased leptin secretion. The increase in circulating
leptin decreases food intake and increases energy ex-
Figure 1. Molecular Control of Adipogenesis penditure, protecting the mice from high fat diet±induced
obesity and insulin resistance. In addition, the elevatedSignals (in vitro differentiation signals 5 glucocorticoids, cAMP,
IGF-1 agonists, and fetal bovine serum; in vivo signals 5 unknown) leptin may modulate insulin sensitivity independently of
interact with stem cells and/or preadipocytes increasing expression its ability to decrease adipose tissue fat stores (Shimo-
of C/EBPb, C/EBPd, and possibly other transcription factors, leading mura et al., 1999).
to modest induction of C/EBPa and potent induction of PPARg.
These findings present the following paradox: bothLigands, possibly fatty acids, increase activity of PPARg. PPARg
PPARg ªoveractivityº due to TZD stimulation and PPARgfurther induces C/EBPa and also increases its own expression. Simi-
ªunderactivityº due to haploinsufficiency protect againstlarly, C/EBPa induces PPARg expression as well as its own expres-
sion. These positive cross-regulation loops ensure that high levels obesity-induced insulin resistance, leading to the some-
of PPARg and C/EBPa are maintained. PPARg then stimulates adi- what perverse, but provocative inference that ªnormalº
pocyte differentiation. Combined high levels of PPARg and C/EBPa amounts of PPARg activity, under certain circum-
promote acquisition of the mature adipocyte phenotype. In the ab- stances, promote disease, and that both agonists and
sence of PPARg, adipocytes fail to develop. In PPARg heterozygous
antagonists of PPARg could be clinically useful. In thismice, adipocytes develop but tend to store less lipid. In the absence
regard, PPARg could be viewed as a ªthrifty gene,º pro-of C/EBPa, adipocytes develop but store less lipid and fail to be-
come insulin sensitive. In the absence of C/EBPb and C/EBPd, adi- moting fat storage to survive starvation when food is
pogenesis is markedly decreased; however, adipocytes that do de- scarce, while producing excessive fat storage leading
velop appear to be normal. to disease when food is plentiful. The paradox also sug-
gests that the two effects are likely to have different
explanations. While the mechanism by which TZD-medi-point may be leptin, the adipocyte-derived circulating
ated stimulation of PPARg improves insulin resistance isproduct of the obese gene which is deficient in ob/ob
not definitively established (Spiegelman, 1998), it seemsmice. The function of leptin is to communicate the status
likely that it is related to PPARg's ability to increase the
of fat stores to the brain, and accordingly, leptin mRNA
number of small adipocytes, by stimulating adipogen-
levels in mature fat cells rise and fall with feeding and
esis, and decrease the number of large adipocytes (re-
fasting. Similarly, leptin expression and secretion is pro-
viewed in Kubota et al., 1999), which are known to pro-
portional to adipocyte size. The cause of this important duce excess amounts of tumor necrosis factor-a and
regulation is unknown but may involve C/EBPa and free fatty acids. PPARg haploinsufficiency, while not af-
PPARg, as these transcription factors have been shown fecting adipogenesis, limits further adipocyte hypertro-
to regulate leptin gene expression. C/EBPa directly and phy, possibly by increasing leptin expression. Although
potently transactivates the proximal leptin promoter (He, the mechanisms are distinct, with TZDs promoting adi-
1995) while TZD-mediated activation of PPARg inhibits pogenesis on the one hand and reduced PPARg gene
leptin gene expression, apparently without binding to dosage decreasing hypertrophy of mature adipocytes
leptin gene regulatory sequences (Hollenberg, 1997). on the other hand, the end result is the sameÐa de-
Such negative regulation by activated PPARg may be creased number of large adipocytes, thus protecting
analagous to the ability of liganded retinoic acid receptor against obesity-induced insulin resistance. The field
(RAR) to inhibit the transcriptional activity of C/EBPb anxiously awaits additional information, both in mice
and C/EBPa, possibly by competing for common, lim- and humans, on the very intriguing ªinsulin-sensitizingº
iting cofactors (Schwarz et al., 1997). effects of PPARg haploinsufficiency.
To investigate the role of PPARg in modulating mature Adipogenesis: Unanswered Questions
adipocyte function, Kubota et al. (1999) studied mice As outlined above, recent years have witnessed a phe-
heterozygous for PPARg deficiency. While these ani- nomenal increase in knowledge regarding the molecular
mals are apparently normal on a regular diet, they are control of adipogenesis. These findings now lead to the
partially resistant to high fat diet±induced obesity and next level of questions. Does an ªexcessº supply of
markedly resistant to the insulin resistance that normally fuel to preadipocytes directly stimulate adipogenesis or
accompanies such obesity. On the surface, this protec- does this induce production in mature adipocytes of a
tion from obesity and insulin resistance could be viewed paracrine signal that secondarily promotes adipogen-
as being due to impaired adipogenesis secondary to esis in neighboring cells? Of particular interest is the
decreased PPARg levels. However, if such a mechanism role of dietary fats to serve as precursors to PPARg
occurred, it would worsen insulin resistance due to ex- ligands. Alternatively, does positive caloric balance alter
systemic hormones, insulin being one example, whichcess deposition of lipid in tissues other than fat, such
Cell
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then stimulate adipogenesis? Do the candidate signals
mentioned above directly engage C/EBPb and/or C/EBPd,
or are other transcription factors involved? Finally, and
importantly, what cell within a fat cell depot, in vivo,
is the adipocyte precursor? Given the identification of
markers such as C/EBPb, C/EBPd, C/EBPa, and PPARg,
this important question should now be addressable.
Based upon recent progress, it is likely that answers to
these questions will be forthcoming.
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